** Shares of telehealth firms WeightWatchers and Hims & Hers Health rise 3.6% and 5.4%, respectively, in premarket trading
** US FDA on Friday said it will reconsider a decision to bar drug compounders from selling their own versions of Eli Lilly's widely popular weight-loss and diabetes drugs
** In response to a lawsuit brought by an industry group, FDA said it would allow compounding facilities to keep providing the drugs while it reviews whether there is a shortage of tirzepatide
** Tirzepatide is the active ingredient in Lilly's Mounjaro and Zepbound, and was removed from the FDA's shortage list in early October
** Both the telehealth firms, and 23 and Me's unit, LemonAid Health, offer compounded versions of semaglutide, the active ingredient in rival drug Wegovy made by Novo Nordisk
** LLY shares down marginally at $930.86, stock has gained ~60% so far this year
** As of last close, WW was down ~81%, while HIMS shares have more than doubled in value YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Comments